Treatment Goals in Psoriatic Arthritis
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 95 |
| Updated: | 1/11/2019 |
| Start Date: | December 20, 2018 |
| End Date: | December 31, 2022 |
| Contact: | Michelle K Jones, BS |
| Email: | mrkjones@jhmi.edu |
| Phone: | 4105509674 |
Are we Meeting Patient Treatment Goals With Guideline-based Therapy for Psoriatic Arthritis
The PaGoPsA study objective is to ascertain if guideline-based psoriatic arthritis clinical
care achieves individual patient goals as articulated by patients, and to identify predictors
of achieving individual patient goals from psoriatic arthritis treatment.
care achieves individual patient goals as articulated by patients, and to identify predictors
of achieving individual patient goals from psoriatic arthritis treatment.
Psoriatic arthritis (PsA) is a heterogeneous autoimmune disease that occurs in one in three
people with the skin disease psoriasis. PsA can cause arthritis (joint inflammation),
enthesitis (tendon and ligament inflammation), sausage digits (swollen entire finger or toe),
spondyloarthritis (spinal inflammation). Skin involvement by psoriasis is also highly
variable in terms of psoriasis type and location. Through combined skin and musculoskeletal
involvement, psoriatic disease has a significant life impact with decrease quality of life
including uncomfortable symptoms, ability to participate in life and functioning. Medications
used to treat PsA have sometimes an uneven effect on the various PsA manifestations where
some are more effective for skin while others more effective for the joints. In this context,
clinical care and treatment of PsA is a complex process which balances disease activity with
medication risks and benefits as well as patient priorities. Professional PsA treatments
guidelines state that PsA treatment goals are disease remission or low disease activity.
Several studies to date have shown that physicians tend to overestimate remission and low
disease activity in PsA patients when compared to disease activity indices. Also patients and
physicians frequently do not align on perceptions of remission or low disease activity. In
the proposed study the investigators aim to identify predictors of successful treatment from
a patient perspective on a range of disease measures including psoriasis, arthritis,
enthesitis, dactylitis, patient reported outcomes, and laboratory assessments which are
routinely collected in the clinical care of PsA. Secondary endpoints are to quantify
longitudinally how stable a state of treatment success is from a patient perspective, and to
define score ranges for disease measurements, including health-related quality of life
measures, that correspond to treatment success from a patient perspective. The impact of this
research is that the investigators will be able to define parameters predictive of achieving
treatment success from a patient perspective, which will then inform goals of care for
psoriatic arthritis.
people with the skin disease psoriasis. PsA can cause arthritis (joint inflammation),
enthesitis (tendon and ligament inflammation), sausage digits (swollen entire finger or toe),
spondyloarthritis (spinal inflammation). Skin involvement by psoriasis is also highly
variable in terms of psoriasis type and location. Through combined skin and musculoskeletal
involvement, psoriatic disease has a significant life impact with decrease quality of life
including uncomfortable symptoms, ability to participate in life and functioning. Medications
used to treat PsA have sometimes an uneven effect on the various PsA manifestations where
some are more effective for skin while others more effective for the joints. In this context,
clinical care and treatment of PsA is a complex process which balances disease activity with
medication risks and benefits as well as patient priorities. Professional PsA treatments
guidelines state that PsA treatment goals are disease remission or low disease activity.
Several studies to date have shown that physicians tend to overestimate remission and low
disease activity in PsA patients when compared to disease activity indices. Also patients and
physicians frequently do not align on perceptions of remission or low disease activity. In
the proposed study the investigators aim to identify predictors of successful treatment from
a patient perspective on a range of disease measures including psoriasis, arthritis,
enthesitis, dactylitis, patient reported outcomes, and laboratory assessments which are
routinely collected in the clinical care of PsA. Secondary endpoints are to quantify
longitudinally how stable a state of treatment success is from a patient perspective, and to
define score ranges for disease measurements, including health-related quality of life
measures, that correspond to treatment success from a patient perspective. The impact of this
research is that the investigators will be able to define parameters predictive of achieving
treatment success from a patient perspective, which will then inform goals of care for
psoriatic arthritis.
Inclusion Criteria:
- English speaking/reading adults
- Patients of the Johns Hopkins Arthritis Center and/or the Johns Hopkins Psoriatic
Arthritis Clinical Program
- Followed every 3-4 months for regular psoriatic arthritis clinical care
- Meet CASPAR classification criteria for psoriatic arthritis
- Able to interact with touch screen computer.
Exclusion Criteria:
We found this trial at
1
site
Baltimore, Maryland 21224
Principal Investigator: Ana-Maria Orbai, MD, MHS
Phone: 410-550-9674
Click here to add this to my saved trials
